Trial Profile

Study to Assess the Safety and Tolerability of Single Doses of REGN1500

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 03 Jul 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Evinacumab (Primary) ; Evinacumab (Primary)
Indications Dyslipidaemias; Hypertriglyceridaemia
Focus Adverse reactions; First in man
Sponsors Regeneron Pharmaceuticals

Most Recent Events

27 Jun 2019 Results from two phase I studies of evinacumab (SAD and MAD studies) published in the Circulation
24 May 2017 Results for Group A (n=83), published in the New England Journal of Medicine
24 May 2017 Results published in the New England Journal of Medicine, according to a Regeneron Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com